Psychedelics have re-emerged as a topic of great interest in recent times, with researchers and clinicians exploring their potential therapeutic applications. The use of psychedelics in modern medicine is not a new idea. However, their use was curtailed post the 1960s Summer Of Love era.
Among the psychedelics that have been studied, LSD (lysergic acid diethylamide), psilocybin (found in "magic mushrooms"), ayahuasca (a plant-based brew), and ketamine have shown promise in various clinical contexts. These substances, whether derived from synthetic sources or occurring naturally, offer a unique approach to addressing mental health conditions that have proven challenging to treat with conventional medications.
From a pharmaceutical perspective, there are interesting questions to consider regards psychedelics, their efficacy and the challenges faced for clinicians and therapists that may prescribe them. First, we should discuss the potential benefits of Psychedelics.
The Potential Benefits of Using Psychedelics:
Psychedelics have demonstrated potential benefits in addressing various mental health conditions. Significant efficacy has been seen when treating anxiety disorders & depression,PTSD,addiction, and cluster headaches. In high (trigger) doses, psychedelic substances alter states of consciousness and facilitate deep introspection, emotional breakthroughs, and enhanced self-awareness. However, in low doses, the effects are often purely cognitive as opposed to fully immersive.
Low doses V psychedelic doses
When it comes to administering psychedelics in a clinical context, there is a critical distinction between low and psychedelic doses, each with pros and cons. Let's explore them.
Low Dose:
Low-dose administration refers to sub-psychedelic doses of psychedelics. Low doses target the neurological effects of the psychedelic, thus utilising the therapeutic potential of these substances while minimising the intensity of the psychedelic experience for the patient. Here are the pros and cons of low-dose therapy:
Pros:
Safety and Manageability: Low doses are generally considered safer and more manageable for patients. The risk of overwhelming psychological experiences or adverse reactions is significantly reduced, making it a suitable option for individuals who may be more sensitive or vulnerable.
Improved Functionality: Low doses may offer therapeutic benefits without impairing cognitive function or inducing intense perceptual distortions. This can allow patients to engage in activities such as psychotherapy sessions, self-reflection, or creative endeavours while benefiting from the subtle effects of the substance.
Cons:
Limited Therapeutic Depth: Low-dose experiences may not reach the same depth or intensity as higher doses, potentially limiting the transformative potential of the therapy.
Some individuals may require a more profound psychedelic experience to access and process underlying emotional or psychological issues effectively.
Psychedelic (Trigger) Dose:
Psychedelic doses involve administering a trigger dose of a psychedelic substance, resulting in intense and transformative experiences. While retaining the neurological effects, a trigger dose will take the patient into the realm of the classic "trip" scenario. This dose level is often linked to the scare-mongering stories perpetuated by many media outlets in the sixties campaign against LSD (Street term, Acid). Here are the pros and cons- of trigger doses.
Pros:
Profound Experiences: Psychedelic doses can induce powerful and transformative experiences, providing patients with opportunities for deep self-reflection, emotional breakthroughs, and expanded consciousness. These experiences may lead to significant and enduring therapeutic effects.
Efficacy in Treatment-Resistant Conditions: Some mental health conditions, such as treatment-resistant depression or PTSD, may require the intensity of a psychedelic dose to initiate substantial therapeutic breakthroughs. Studies have shown varying results in using psychedelic doses for these challenging conditions.
Cons:
Intensity and Overwhelm: Psychedelic doses can be overwhelming, with intense perceptual alterations, emotional states, and ego dissolution. These experiences may be challenging to navigate for specific individuals and require skilled therapists and a supportive environment.
Safety and Risk Management: Higher doses increase the risk of adverse reactions, including psychological distress, panic, or acute anxiety. Close monitoring, proper preparation, and skilled facilitators are necessary to mitigate these risks effectively.
Ultimately, deciding between low and psychedelic doses depends on the specific therapeutic goals, patient characteristics, and sound clinical judgement. Tailoring the dosage to the individual's needs and closely monitoring their response can help optimise the therapeutic outcomes while ensuring their safety and well-being.
Clinically Improved Derivatives vs Naturally Occurring Compounds:
In addition to naturally occurring psychedelics like psilocybin and ayahuasca, clinically improved derivatives have gained attention. The debate as to whether a therapist should utilise natural compounds over synthesised products is complex and largely unstudied. Like Marijuana, natural psychedelics are readily available, although relatively complex to grow.
Arguably, the Synthesis of psychedelic compounds allows the opportunity to tailor their effects, design easier-to-utilise products and increase availability to those that would benefit from them while simultaneously controlling their availability on the street.
Examples of natural psychedelics.
Psilocybin is a naturally occurring psychedelic compound derived from various species of mushrooms. It belongs to a class of compounds called tryptamines and is known for its mind-altering effects. When ingested, psilocybin is converted into psilocin, which interacts with serotonin receptors in the brain, leading to altered perception, sensory experiences, and changes in thought patterns.
Psilocybin has a long history of use in spiritual and cultural practices, and in recent years, it has gained attention for its potential therapeutic applications in the treatment of mental health conditions, such as depression, anxiety, and PTSD.
Ayahuasca, a plant-based brew containing the psychedelic compound DMT, has been utilised in traditional Amazonian practices and has garnered interest in modern medicine. Ayahuasca-assisted therapy has shown promise in treating conditions such as depression, addiction, and PTSD. Research has highlighted its rapid and sustained antidepressant effects and potential to reduce cravings and enhance motivation for change in individuals struggling with substance use disorders.
Examples of synthesised psychedelic compounds.
LSD, initially synthesised in a laboratory as a potential respiratory medicine, has demonstrated promise in clinical trials for anxiety disorders and depression. Its use in conjunction with psychotherapy has significantly reduced anxiety and depressive symptoms.
Similarly, ketamine (and its derivative esketamine), originally an anaesthetic, has been repurposed for its rapid-acting antidepressant effects. When administered in controlled settings, ketamine has shown efficacy in treating treatment-resistant depression and rapidly relieves depressive symptoms.
Why were psychedelic therapies abandoned?
As psychedelics have been associated with modern medicine in the past, and allegorical evidence of the ancient ceremonial use of psychedelics exists, why were they demonised and classified as a schedule I (US) Class A (UK)?
The classification of LSD as a Schedule I substance and other psychedelics resulted from various societal and political factors rather than a reflection of its therapeutic potential. Understanding the context behind this classification sheds light on why LSD faced regulatory challenges despite its promising therapeutic properties.
1. Cultural and Political Climate:
In the 1960s, LSD gained popularity within counterculture movements and became associated with anti-establishment sentiments. The substance was perceived as threatening societal norms and the existing power structures. Additionally, fears surrounding recreational use, public safety concerns, and potential abuse contributed to the cultural and political climate that led to increased regulatory control.
2. Misinformation and Exaggerated Reports:
As LSD gained public attention, exaggerated reports and sensationalized stories emerged, often portraying the substance as dangerous and capable of causing severe harm. These reports overshadowed the scientific research conducted during that period, leading to public panic and pressure on regulatory bodies to restrict its use.
3. Lack of Rigorous Scientific Research:
While early research showed promise in exploring LSD's therapeutic potential, the scientific community faced limitations in conducting comprehensive studies due to the increasing regulatory restrictions. This lack of research impeded the accumulation of robust evidence to counterbalance the negative perceptions associated with the substance.
4. Public Health and Safety Concerns:
Some instances of individuals experiencing adverse psychological reactions to LSD, particularly in uncontrolled environments or high-dose settings, raised concerns about the substance's safety. Although not reflective of most experiences, these isolated incidents influenced public perception and fueled arguments for regulatory control.
5. Shifting Societal Attitudes:
As the counterculture movement waned and the societal and political landscape shifted, attitudes towards psychedelics evolved. The perceived risks associated with LSD overshadowed its therapeutic potential, leading to stricter regulatory measures and its classification as a Schedule I substance.
It would appear that the landscape is changing, and contemporary research is again shedding light on the potential benefits of psychedelics in therapeutic settings. The re-evaluation of psychedelics' classification and the emergence of new scientific evidence are gradually reshaping regulatory frameworks to allow for further exploration of their therapeutic applications.
However, the road to administering psychedelics, even if re-scheduled and commonly accepted, is not easy.
Challenges Faced When Using Psychedelics Within a Clinical Environment:
Despite the promising therapeutic potential of psychedelics, their use within a clinical environment presents specific challenges. Safety considerations, such as the potential for adverse reactions and the need for proper supervision, require careful management. The intensity of psychedelic experiences may be overwhelming for some individuals, necessitating skilled therapists and supportive integration processes.
The cost of providing usable spaces for the more intensive and immersive therapies must also be considered. Medical facilities, with strange equipment and staff in white coats, while bearable as a patient under normal circumstances, could become triggering for those on a more profound trip.
Prolonged regulatory restrictions and societal stigmas associated with psychedelics have impeded scientific research and limited the accumulation of evidence. Standardised protocols, dosing guidelines, and long-term safety profiles remain unestablished. Despite these factors, psychedelics have re-emerged as a promising area of exploration in modern medicine. LSD, psilocybin, ayahuasca, and ketamine, whether occurring naturally or as clinically improved derivatives, offer unique therapeutic opportunities for mental health conditions. Careful consideration of dosage, safety protocols, and integration processes will contribute to the responsible and effective use of psychedelics in clinical settings.
As research continues to unfold, psychedelics have the potential to reshape the treatment landscape, providing alternative options for individuals who have not responded to traditional therapies. The reevaluation of regulatory frameworks and the growing acceptance of psychedelics in medical and scientific communities pave the way for further exploration of their therapeutic applications.
While challenges exist, the therapeutic potential of psychedelics in modern medicine is undeniable. Their ability to facilitate profound experiences, promote introspection, and potentially address treatment-resistant mental health conditions offers hope for individuals who have struggled to find relief through conventional treatments. Continued research, rigorous clinical trials, and responsible implementation will be critical to fully unlocking the therapeutic benefits of psychedelics and integrating them into evidence-based practices.
As public perception and regulatory attitudes evolve, it is crucial to approach psychedelics in a balanced and informed manner. Rigorous scientific investigation, proper education, and responsible use are paramount to ensure psychedelics' safe and effective integration into modern medicine. By embracing the potential of psychedelics and fostering a collaborative approach among researchers, clinicians, and regulatory bodies, we can unlock new frontiers in mental health care and enhance the well-being of countless individuals.
Psychedelics hold great promise as a transformative force in modern medicine. Exploring their therapeutic potential, ranging from low doses to psychedelic experiences, and using clinically improved derivatives and naturally occurring compounds represents a paradigm shift in mental health treatment. Through continued research, responsible practice, and open dialogue, we can harness the power of psychedelics to address the complex challenges of mental health disorders, ultimately improving the lives of individuals.
